ARCHIVES

Minority Accrual Low In Prevention Trials; NCI Plans Programs To Boost enrollment

This article is from The Cancer Letter archive.

Vol. 22 No. 05 | February 2, 1996

Download PDF Visit The Full Archive

Related Articles

World Conference To Consider Smoking Problem, Research, Action

March 14, 1975

Urologists support Approval Of Il-2 for Kidney Cancer

February 1, 1991

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

NABCO to close June 30.

January 30, 2004

Obituary: Piotr Kulesza, 46, Pathologist At Northwestern, ECOG-ACRIN, Dies in Fall After Group Meeting

November 22, 2013

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012